- Home
- TXMD vs CWD Comparison
TXMD vs CWD Comparison
Compare TXMD & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- CWD
- Stock Information
- Founded
- TXMD 2008
- CWD 2009
- Country
- TXMD United States
- CWD United States
- Employees
- TXMD N/A
- CWD N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- TXMD Health Care
- CWD Finance
- Exchange
- TXMD Nasdaq
- CWD Nasdaq
- Market Cap
- TXMD 12.8M
- CWD 12.1M
- IPO Year
- TXMD N/A
- CWD 2023
- Fundamental
- Price
- TXMD $1.00
- CWD $0.63
- Analyst Decision
- TXMD
- CWD
- Analyst Count
- TXMD 0
- CWD 0
- Target Price
- TXMD N/A
- CWD N/A
- AVG Volume (30 Days)
- TXMD 113.1K
- CWD 74.3K
- Earning Date
- TXMD 03-28-2025
- CWD 03-20-2025
- Dividend Yield
- TXMD N/A
- CWD N/A
- EPS Growth
- TXMD N/A
- CWD N/A
- EPS
- TXMD N/A
- CWD N/A
- Revenue
- TXMD $1,596,000.00
- CWD $66,376,999.00
- Revenue This Year
- TXMD $605.07
- CWD N/A
- Revenue Next Year
- TXMD $1.11
- CWD $38.91
- P/E Ratio
- TXMD N/A
- CWD N/A
- Revenue Growth
- TXMD N/A
- CWD N/A
- 52 Week Low
- TXMD $0.70
- CWD $0.37
- 52 Week High
- TXMD $2.75
- CWD $1.26
- Technical
- Relative Strength Index (RSI)
- TXMD 41.47
- CWD 52.87
- Support Level
- TXMD $0.99
- CWD $0.50
- Resistance Level
- TXMD $1.13
- CWD $0.66
- Average True Range (ATR)
- TXMD 0.06
- CWD 0.05
- MACD
- TXMD -0.00
- CWD -0.00
- Stochastic Oscillator
- TXMD 5.26
- CWD 65.67
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.